Guardant Health, Inc.
GH
Services-Medical Laboratories
Mkt Cap
$3.184BPE
-6.91Debt
$1.141BCash
$1.129BEV
$3.195BFCF
-$300.7MP/E Ratio
-6.91Debt
$1.141BCash
$1.129BEV
$3.195BFCF
-$300.7MCharts data: {"Earnings":[{"time":"2016-12-30","value":-46139000},{"time":"2017-12-30","value":-88995000},{"time":"2018-12-30","value":-85063000},{"time":"2019-12-30","value":-75651000},{"time":"2020-12-30","value":-253783000},{"time":"2021-12-30","value":-405670000},{"time":"2022-12-30","value":-654588000},{"time":"2023-12-30","value":-479449000}],"Sales":[{"time":"2016-12-30","value":25249000},{"time":"2017-12-30","value":49842000},{"time":"2018-12-30","value":90639000},{"time":"2019-12-30","value":214375000},{"time":"2020-12-30","value":286730000},{"time":"2021-12-30","value":373653000},{"time":"2022-12-30","value":449538000},{"time":"2023-12-30","value":563948000}],"Net Margins":[{"time":"2016-12-30","value":-1.8273594993861142},{"time":"2017-12-30","value":-1.7855423137113278},{"time":"2018-12-30","value":-0.9384812277275786},{"time":"2019-12-30","value":-0.35289096209912535},{"time":"2020-12-30","value":-0.8850939908624839},{"time":"2021-12-30","value":-1.0856864524037007},{"time":"2022-12-30","value":-1.4561349652309705},{"time":"2023-12-30","value":-0.8501652634640073}],"Assets":[{"time":"2017-12-30","value":342938000},{"time":"2018-12-30","value":587403000},{"time":"2019-12-30","value":962535000},{"time":"2020-12-30","value":2271781000},{"time":"2021-12-30","value":2204499000},{"time":"2022-12-30","value":1609985000},{"time":"2023-12-30","value":1786421000}],"Stockholders Equity":[{"time":"2016-12-30","value":79696000},{"time":"2017-12-30","value":308606000},{"time":"2018-12-30","value":483152000},{"time":"2019-12-30","value":798393000},{"time":"2020-12-30","value":1298495000},{"time":"2021-12-30","value":645005000},{"time":"2022-12-30","value":60180000},{"time":"2023-12-30","value":158684000}],"ROE":[{"time":"2016-12-30","value":-0.5789374623569564},{"time":"2017-12-30","value":-0.2883774132712909},{"time":"2018-12-30","value":-0.1760584660727887},{"time":"2019-12-30","value":-0.09475408727280926},{"time":"2020-12-30","value":-0.19544395627245387},{"time":"2021-12-30","value":-0.6289408609235587},{"time":"2022-12-30","value":-10.87716849451645},{"time":"2023-12-30","value":-3.0214073252501827}],"ROA":[{"time":"2017-12-30","value":-0.2233989817401396},{"time":"2018-12-30","value":-0.14125566263706518},{"time":"2019-12-30","value":-0.07120987808235545},{"time":"2020-12-30","value":-0.10614491449659981},{"time":"2021-12-30","value":-0.17440243792353727},{"time":"2022-12-30","value":-0.33812613160992183},{"time":"2023-12-30","value":-0.2680017756172817}]}
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
![LH Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>LH</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -180% | -180% | -94% | -35% | -89% | -110% | -150% | -85% | -76% |
| ROA | - | -22% | -14% | -7.1% | -11% | -17% | -34% | -27% | -26% |
| ROE | -58% | -29% | -18% | -9.5% | -20% | -63% | -1.1K% | -300% | -670% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -92.81%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -8.77%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -18.32%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -4.29%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -249.9%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -134.31%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | 0.00 | -5.76 | -4.00 | -2.94 | -3.30 | -3.79 | |
| Debt Equity | - | - | - | 0.00 | 0.62 | 1.76 | 18.90 | 7.18 | 16.70 | |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -3.79.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.38.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 56% | 44% | 25% | 25% | -16% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 10% | -20% | -50% | 160% | -28% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +44.14%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -15.9%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +41.32%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -19.96%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -27.88%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +30.18%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.